[go: up one dir, main page]

MA39554B1 - Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock - Google Patents

Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock

Info

Publication number
MA39554B1
MA39554B1 MA39554A MA39554A MA39554B1 MA 39554 B1 MA39554 B1 MA 39554B1 MA 39554 A MA39554 A MA 39554A MA 39554 A MA39554 A MA 39554A MA 39554 B1 MA39554 B1 MA 39554B1
Authority
MA
Morocco
Prior art keywords
compounds
rock inhibitors
spirocycloheptanes
formula
relates
Prior art date
Application number
MA39554A
Other languages
English (en)
Other versions
MA39554A2 (fr
MA39554A3 (fr
Inventor
Yufeng Wang
Vladimir Ladziata
Peter W Glunz
Zilun Hu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA39554A2 publication Critical patent/MA39554A2/fr
Publication of MA39554A3 publication Critical patent/MA39554A3/fr
Publication of MA39554B1 publication Critical patent/MA39554B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (i) ou des stéréo-isomères, des tautomères ou des sels de qualité pharmaceutique de ceux-ci. Dans ladite formule, toutes les variables ont la signification indiquée dans la description. Ces composés sont des inhibiteurs sélectifs de rock. L'invention concerne également des compositions pharmaceutiques qui comprennent ces composés ainsi que des méthodes pour traiter des troubles cardiovasculaires, des muscles lisses, oncologiques, neuropathologiques, auto-immuns, fibrotiques, et/ou inflammatoires à l'aide desdites compositions.
MA39554A 2014-07-15 2015-07-14 Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock MA39554B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024555P 2014-07-15 2014-07-15
US14/797,414 US9902702B2 (en) 2014-07-15 2015-07-13 Spirocycloheptanes as inhibitors of rock
PCT/US2015/040254 WO2016010950A1 (fr) 2014-07-15 2015-07-14 Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock

Publications (3)

Publication Number Publication Date
MA39554A2 MA39554A2 (fr) 2018-01-31
MA39554A3 MA39554A3 (fr) 2019-05-31
MA39554B1 true MA39554B1 (fr) 2020-05-29

Family

ID=55073996

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39554A MA39554B1 (fr) 2014-07-15 2015-07-14 Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock

Country Status (24)

Country Link
US (2) US9902702B2 (fr)
EP (1) EP3169682B1 (fr)
JP (2) JP6499749B2 (fr)
KR (1) KR102420938B1 (fr)
CN (1) CN106817899B (fr)
AR (1) AR101208A1 (fr)
AU (1) AU2015289897B2 (fr)
BR (1) BR112017000808A2 (fr)
CA (1) CA2954976A1 (fr)
CL (1) CL2017000089A1 (fr)
CO (1) CO2017001152A2 (fr)
EA (1) EA033061B1 (fr)
ES (1) ES2716415T3 (fr)
IL (1) IL250046B (fr)
MA (1) MA39554B1 (fr)
MX (1) MX376178B (fr)
PE (1) PE20170672A1 (fr)
PH (1) PH12017500072A1 (fr)
SG (1) SG11201700251PA (fr)
TN (1) TN2017000009A1 (fr)
TW (1) TW201607933A (fr)
UY (1) UY36215A (fr)
WO (1) WO2016010950A1 (fr)
ZA (1) ZA201700304B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
EP3242873B1 (fr) 2015-01-09 2020-07-22 Bristol-Myers Squibb Company Urées cycliques utiles en tant qu'inhibiteurs de rock
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
EP3268360B1 (fr) 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactames utilisés en tant qu'inhibiteurs de rho-kinases (rock)
DK3340796T3 (da) * 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein
AR107354A1 (es) * 2016-01-13 2018-04-18 Bristol Myers Squibb Co Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock
EP3464262B1 (fr) 2016-05-27 2020-02-26 Bristol-Myers Squibb Company Utilisation de triazolones et de tétrazolones comme inhibiteurs de la voie de signalisation rho/rock
WO2017214413A1 (fr) * 2016-06-08 2017-12-14 Chrysalis, Inc. Dérivés d'imidazo[1,2-a]pyridine utilisés en tant qu'inhibiteurs d'histone déméthylase
JP7113810B2 (ja) 2016-07-07 2022-08-05 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロラクタム
KR102473481B1 (ko) * 2016-07-07 2022-12-01 브리스톨-마이어스 스큅 컴퍼니 강력하고 선택적인 rock 억제제로서의 락탐, 시클릭 우레아 및 카르바메이트, 및 트리아졸론 유도체
KR102449652B1 (ko) 2016-07-07 2022-09-29 브리스톨-마이어스 스큅 컴퍼니 Rock의 억제제로서의 스피로-융합 시클릭 우레아
JP7191826B2 (ja) 2016-11-30 2022-12-19 ブリストル－マイヤーズ スクイブ カンパニー 三環式ｒｈｏキナーゼ阻害剤
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
JP7117306B2 (ja) * 2016-12-21 2022-08-12 バイオアクソン バイオサイエンシーズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物
PE20191744A1 (es) * 2017-01-30 2019-12-12 Chiesi Farm Spa Derivados de tirosinamida como inhibidores de rho-quinasa
CN110582491B (zh) * 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN111217797B (zh) 2017-06-30 2021-02-05 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019014322A1 (fr) 2017-07-11 2019-01-17 BioAxone BioSciences, Inc. Inhibiteurs de kinase pour le traitement de maladies
EP3652165B1 (fr) 2017-07-12 2021-08-25 Bristol-Myers Squibb Company INHIBITEURS DE ROCK AMINOHETEROCYCLIQUE À CINQ CHAÎNONS
ET AMINOHÉTÉROCYCLIQUES BICYCLIQUES À CHAÎNONS 5,6 OU 6,6 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
KR102680164B1 (ko) 2017-07-12 2024-07-01 브리스톨-마이어스 스큅 컴퍼니 Rock 억제제로서의 페닐아세트아미드
JP7313331B2 (ja) * 2017-07-12 2023-07-24 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロヘプタニルヒダントイン
US12060341B2 (en) * 2017-07-12 2024-08-13 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as ROCK inhibitors
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
EA202090485A1 (ru) 2017-08-14 2020-05-27 Эпизайм, Инк. Способы лечения рака путем ингибирования setd2
AU2018326785B2 (en) * 2017-09-03 2023-03-02 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
ES2937039T3 (es) 2017-11-03 2023-03-23 Bristol Myers Squibb Co Inhibidores diazaespiro de ROCK
JP7627209B2 (ja) 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
WO2020048596A1 (fr) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Nouveaux composés de pyrazolopyridine pour le traitement d'une maladie auto-immune
EP3999038B1 (fr) * 2019-07-17 2024-01-10 Cytokinetics, Inc. Formulations perorales d'inhibiteur de sarcomères cardiaques
WO2021257857A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
CA3188639A1 (fr) 2020-07-02 2022-01-06 Incyte Corporation Composes d'uree tricycliques en tant qu'inhibiteurs de v617f de jak2
WO2022006456A1 (fr) 2020-07-02 2022-01-06 Incyte Corporation Composés de pyridone tricyclique en tant qu'inhibiteurs de v617f de jak2
TWI854147B (zh) * 2020-08-21 2024-09-01 南韓商治納輔醫藥科技有限公司 對前列腺素e2受體具有抑制活性的新穎化合物及其用途
WO2022046989A1 (fr) 2020-08-27 2022-03-03 Incyte Corporation Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2
JP2023550260A (ja) * 2020-11-25 2023-12-01 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症の処置および予防のための芳香族スピロ環アミド誘導体
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
EP4298099A1 (fr) 2021-02-25 2024-01-03 Incyte Corporation Lactames spirocycliques utilisés comme inhibiteurs du v617f de jak2
WO2022237878A1 (fr) * 2021-05-14 2022-11-17 武汉朗来科技发展有限公司 Forme cristalline de composé, composition contenant la forme cristalline, son procédé de préparation et son utilisation
CN113861223B (zh) * 2021-09-07 2022-09-16 暨南大学 一种噻唑并[3,2-a]苯并咪唑类化合物的合成方法及其应用
JP2025509672A (ja) 2022-03-17 2025-04-11 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物
JP2025511160A (ja) * 2022-04-01 2025-04-15 サノフイ ピラゾロピラジノン化合物、その調製のための方法及びその治療的使用
TW202402269A (zh) * 2022-05-26 2024-01-16 大陸商迪哲（江蘇）醫藥股份有限公司 ＲＯＣＫ（Ｒｈｏ相關激酶）抑制劑及其用途
CN115894141B (zh) * 2022-10-13 2023-12-22 贺州学院 酰基茚烷类衍生物的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2531776A1 (de) 1975-07-16 1977-02-03 Basf Ag Azopigmente mit einem phthalazonrest
TW245719B (fr) 1990-09-10 1995-04-21 Sterling Winthrop Inc
DE69110828T2 (de) 1990-10-16 1995-11-30 Takeda Chemical Industries Ltd Heterozyklische Aminderivate, deren Herstellung und deren Verwendung.
EP0634402A1 (fr) 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Dérivés d'isoquinolinone, leur production et utilisation
AU6230098A (en) 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
DE19804085A1 (de) 1998-02-03 1999-08-05 Boehringer Ingelheim Pharma 5-Gliedrige heterocyclische kondensierte Benzoderivate, deren Herstellung und deren Verwendung als Arzneimittel
WO1999040072A1 (fr) 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg Heterocycles benzo condenses a 5 chainons utilises comme agents antithrombotiques
JP2000072675A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd 医薬組成物
EP1148053A4 (fr) 1999-01-26 2002-03-06 Ono Pharmaceutical Co Derives 2h-phthalazine-1-one et medicaments renfermant ces derives comme principe actif
DE19907813A1 (de) 1999-02-24 2000-08-31 Boehringer Ingelheim Pharma Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel
NZ525138A (en) 2000-10-30 2004-03-26 Kudos Pharm Ltd Phthalazinone derivatives for use as PARP inhibitors
WO2003068750A1 (fr) 2002-02-13 2003-08-21 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
AU2003264386A1 (en) 2002-09-10 2004-04-30 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP2008514636A (ja) 2004-09-28 2008-05-08 アンジオン バイオメディカ コーポレイション サイトカイン活性の低分子モジュレーター
WO2006124874A2 (fr) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
CN101296904A (zh) * 2005-07-11 2008-10-29 德福根有限公司 作为激酶抑制剂的酰胺衍生物
ATE478865T1 (de) * 2006-05-12 2010-09-15 Vertex Pharma Selektive rock-proteinkinasehemmer und ihre verwendung
RU2008152065A (ru) * 2006-06-08 2010-07-20 Убе Индастриз, Лтд (Jp) Новое производное имидазола со спироциклической структурой в боковой цепи
EP2526948A1 (fr) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. Inhibiteurs de la RHO-kinase
JP5405314B2 (ja) * 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノロン誘導体
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
WO2008086014A2 (fr) 2007-01-09 2008-07-17 Amgen Inc. Dérivés de bis-aryl amide et procédés d'utilisation
WO2009064422A2 (fr) 2007-11-13 2009-05-22 Angion Biomedica Corp. Activateurs des voies du facteur de croissance hépatocytaire dans les maladies des tissus conjonctifs fibrotiques
WO2011019400A2 (fr) 2009-08-12 2011-02-17 Angion Biomedica Corp. Amélioration d’une transplantation cellulaire en utilisant des modulateurs à petite molécule de l’activité de facteur de croissance d’hépatocyte (scatter factor)
BR112013012078A2 (pt) 2010-11-15 2019-09-24 Abbvie Inc inibidores de nampt e rock
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
CN102180909B (zh) 2011-03-18 2014-10-22 南京邮电大学 以酞嗪衍生物为配体的铱配合物磷光材料及其制备方法
CN102327275B (zh) * 2011-09-07 2013-03-20 苏州大学 3-[4-(磺酰)苯]脲类化合物在制备抗肿瘤药物中的应用
CN102432612B (zh) * 2011-09-07 2014-09-17 苏州大学 4,7-二氢四唑[1,5-a]嘧啶衍生物及其在制备抗肿瘤药物中的应用
WO2014079850A1 (fr) 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Dérivés hétérocycliques substitués
US9926282B2 (en) 2013-01-18 2018-03-27 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as rock inhibitors
EP2961746B1 (fr) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
US9102684B2 (en) * 2013-03-27 2015-08-11 Boehringer Ingelheim International Gmbh Indolinone analogues
CN103242647B (zh) 2013-04-27 2015-06-17 大连理工大学 一种阻燃耐热聚氨酯泡沫塑料及其制备方法
ES2634628T3 (es) 2013-07-02 2017-09-28 Bristol-Myers Squibb Company Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK
US9914740B2 (en) 2013-07-02 2018-03-13 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EP3097090B1 (fr) 2014-01-20 2018-10-10 F. Hoffmann-La Roche AG Dérivés de n-phényl-lactame aptes à stimuler la neurogenèse et leur utilisation dans le traitement des désordres neurologiques
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock

Also Published As

Publication number Publication date
EP3169682A1 (fr) 2017-05-24
MA39554A2 (fr) 2018-01-31
TN2017000009A1 (en) 2018-07-04
CO2017001152A2 (es) 2017-05-19
JP6721741B2 (ja) 2020-07-15
ZA201700304B (en) 2018-12-19
KR20170023187A (ko) 2017-03-02
SG11201700251PA (en) 2017-02-27
AR101208A1 (es) 2016-11-30
KR102420938B1 (ko) 2022-07-14
EA201790062A1 (ru) 2017-08-31
AU2015289897B2 (en) 2019-07-18
EA033061B1 (ru) 2019-08-30
PE20170672A1 (es) 2017-05-22
EP3169682B1 (fr) 2018-12-26
US20160016914A1 (en) 2016-01-21
TW201607933A (zh) 2016-03-01
MX376178B (es) 2025-03-07
AU2015289897A1 (en) 2017-03-09
CA2954976A1 (fr) 2016-01-21
MA39554A3 (fr) 2019-05-31
MX2017000485A (es) 2017-04-27
US9902702B2 (en) 2018-02-27
BR112017000808A2 (pt) 2017-12-05
CN106817899A (zh) 2017-06-09
PH12017500072A1 (en) 2017-05-15
WO2016010950A1 (fr) 2016-01-21
ES2716415T3 (es) 2019-06-12
CN106817899B (zh) 2021-03-09
IL250046B (en) 2020-03-31
JP6499749B2 (ja) 2019-04-10
JP2019112447A (ja) 2019-07-11
CL2017000089A1 (es) 2017-09-15
UY36215A (es) 2016-01-29
JP2017520604A (ja) 2017-07-27
US20180155296A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
MA39554B1 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA42145B1 (fr) Triazoles agonistes du récepteur apj
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA39225A1 (fr) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA39972A (fr) Composés et compositions d'induction de la chondrogenèse
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA39927B1 (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA46965B1 (fr) Modulateurs de gamma ror (rory)
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
MA52331A1 (fr) Macrocycles à groupes hétérocycliques p2' servant d'inhibiteurs du facteur xia
MA44144B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45392B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs